MXCT MAXCYTE, INC. Insider Trading

Director Douglas Richard bought 80,000 shares of MXCT at $1.39 on 2025-08-13 in cluster-buy pattern while stock down -72.9% from 52-week high.

Douglas Richard, a director at MaxCyte, purchased 80,000 shares at $1.39, increasing his holdings from 150,577 to 230,577 shares (+53.1%). The transaction occurs as the stock trades -72.9% below its 52-week high of $5.10 and has declined -38.4% over the past 30 days. Notably, this purchase is part of a broader pattern: four other insiders also bought within the past 14 days, suggesting coordinated interest at depressed price levels. However, the company remains unprofitable with net income of $-12,357,000.00 in the latest quarter and full-year net income negative, alongside declining annual revenue growth of -6.4%, creating a structural tension between insider accumulation and deteriorating fundamentals that warrants close investor scrutiny.

Director Brooke William W buys 50,000 MXCT shares at $1.29; 4 other insiders bought in past 14 days amid -72.9% YTD decline

Director Brooke William W purchased 50,000 shares at $1.29, increasing his holdings by 49.6% to 150,879 shares. This transaction is part of a cluster pattern: 4 other insiders also bought within the past 14 days. The cluster buy coincides with material stock weakness—the stock is down 72.9% from its 52-week high of $5.10 and down 38.4% over the past 30 days. The company is unprofitable with a negative net income of $-12.4M in its most recent full fiscal year and revenue declining 6.4% year-over-year, though its market cap remains $147.1M. The concurrence of insider accumulation across multiple directors during a period of severe price pressure and negative fundamentals warrants close monitoring of underlying business trajectory and insider conviction.

Director Erck Stanley C bought 100,000 shares of MXCT at $1.37 on 2025-08-13; 4 insiders bought within 14 days as stock down -72.9% from 52-week high.

Director Erck Stanley C purchased 100,000 shares at $1.37, increasing holdings by 33.5% to 398,328 shares. This transaction is part of a cluster pattern: 4 other insiders also bought within the past 14 days, suggesting coordinated insider accumulation despite challenging company fundamentals. MXCT is currently unprofitable with net income of $-12,357,000.00 over its most recent full fiscal year, annual revenue decline of -6.4%, and a stock price that has fallen -72.9% from its 52-week high of $5.10. The concentration of director-level buying during a period of severe price weakness and negative earnings warrants evaluation of whether these purchases reflect underlying operational recovery signals or represent a contrarian stance during distressed valuation conditions.

MXCT CEO Masoud Maher bought 75,000 shares at $1.37 (Aug 13); stock down 72.9% from 52-week high, cluster of 4 other insider buys in 14 days

Masoud Maher, President and CEO, purchased 75,000 shares at $1.37 on 2025-08-13, increasing his holdings from 100,000 to 175,000 shares (75.0% increase). The transaction occurs against a severely depressed price backdrop: the stock trades at $1.38 today, -72.9% from the 52-week high of $5.10, and down -38.4% over the past 30 days. At the same-ticker level, Maher's two prior purchases in June 2024 delivered negative returns at both the 30-day and 90-day horizons, with 0 of 2 buys proving well-timed at the 90-day mark. The company fundamentals are challenging: latest quarterly revenue is $8.5M with a net loss of $-12.4M; annual revenue declined -6.4% year-over-year, and the firm was unprofitable over the most recent full fiscal year. Notably, 4 other insiders also purchased shares within the past 14 days, creating a cluster buy pattern. This synchronized buying by multiple insiders at extreme lows, combined with Maher's poor historical timing at this specific ticker and the company's negative earnings and declining revenue, presents a factual pattern warranting investor scrutiny of the underlying rationale.

CFO Douglas J Swirsky buys 50,000 shares at $1.29; 4-insider cluster buy amid -72.9% decline from 52-week high

On 2025-08-13, CFO Douglas J Swirsky purchased 50,000 shares of MAXCYTE, INC. (MXCT) at $1.29, increasing his holdings by 44.7% to 161,811 shares. This transaction is notable because it occurs within a cluster pattern: 4 other insiders also bought within the past 14 days. The stock currently trades at $1.38, down 72.9% from its 52-week high of $5.10, and the company is unprofitable with net income of $-12.4M on quarterly revenue of $8.5M. The synchronized buying activity by multiple insiders at severely depressed prices following substantial declines warrants examination of whether this reflects asymmetric information or merely presents a valuation opportunity.